Literature DB >> 18604512

[Hemoptysis and acute renal failure in a 29-year-old patient with chronic hepatitis C infection].

J Marx1, V Schwenger, N Blank, W Stremmel, J Encke.   

Abstract

A 29-year-old male patient with chronic hepatitis C infection and interferon alpha therapy in his medical history was admitted to the hospital because of the clinical manifestation of a pulmonary renal syndrome. High titers of proteinase-3-ANCA were detected, while an infectious agent was ruled out. After diagnosis of Wegener's granulomatosis the patient received prednisolone and cyclophosphamide pulse therapy and remission developed rapidly. Chronic hepatitis C infection as well as interferon therapy are frequently associated with autoimmune disorders. We assume that the interferon therapy itself has triggered autoimmune processes resulting in Wegener's granulomatosis in our patient. Thus we recommend to search specifically for autoimmune disorders in the past medical history and if necessary to consider a screening for autoantibodies before starting an interferon therapy. An autoimmune disease should also be taken into account if new symptoms develop under an ongoing interferon alpha therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18604512     DOI: 10.1007/s00108-008-2099-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  13 in total

Review 1.  Side effects of therapy of hepatitis C and their management.

Authors:  Michael W Fried
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 2.  Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy.

Authors:  P Fabris; A Floreani; G Tositti; D Vergani; F De Lalla; C Betterle
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

Review 3.  Antineutrophil cytoplasmic antibodies.

Authors:  Xavier Bosch; Antonio Guilabert; Josep Font
Journal:  Lancet       Date:  2006-07-29       Impact factor: 79.321

4.  Clinical problem-solving. Sum of the parts.

Authors:  Meeta Prasad; Gregory K Buller; Carlos I Mena; André N Sofair
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

5.  Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C.

Authors:  N K Gatselis; S P Georgiadou; G K Koukoulis; N Tassopoulos; K Zachou; C Liaskos; A Hatzakis; G N Dalekos
Journal:  Aliment Pharmacol Ther       Date:  2006-11-10       Impact factor: 8.171

Review 6.  Cryoglobulins.

Authors:  C Ferri; A L Zignego; S A Pileri
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

7.  Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.

Authors:  R Pellicano; A Smedile; S Peyre; M Astegiano; G Saracco; R Bonardi; M Rizzetto
Journal:  Minerva Gastroenterol Dietol       Date:  2005-03

Review 8.  Update in the diagnosis and management of pulmonary vasculitis.

Authors:  Stephen K Frankel; Gregory P Cosgrove; Aryeh Fischer; Richard T Meehan; Kevin K Brown
Journal:  Chest       Date:  2006-02       Impact factor: 9.410

9.  High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.

Authors:  B D Clifford; D Donahue; L Smith; E Cable; B Luttig; M Manns; H L Bonkovsky
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

Review 10.  Autoimmune disease complicating antiviral therapy for hepatitis C virus infection.

Authors:  Leslie E Wilson; David Widman; Steven H Dikman; Peter D Gorevic
Journal:  Semin Arthritis Rheum       Date:  2002-12       Impact factor: 5.532

View more
  3 in total

Review 1.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

Review 2.  [Cryoglobulinemic vasculitis].

Authors:  N Blank; H-M Lorenz
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

3.  Antineutrophil cytoplasmic antibody frequency in chronic hepatitis B patients.

Authors:  Turan Calhan; Abdurrahman Sahin; Resul Kahraman; Mustafa Erhan Altunoz; Fatma Ozbakır; Kamil Ozdil; Hacı Mehmet Sokmen
Journal:  Dis Markers       Date:  2014-08-05       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.